BREAKING! Peer Reviewed Swiss Study Shows That mRNA-1273 Vaccine-Associated Myocardial Injury IS More Common Than Previously Thought!
COVID-19 News - mRNA-1273 Vaccine-Associated Myocardial Injury Jul 28, 2023 1 year, 3 months, 3 weeks, 4 days, 7 hours, 49 minutes ago
Study by the University of Basel shows that one in 35 people who received the COVID-19 mRNA booster vaccinations had vaccine-associated myocardial injury!
COVID-19 News: The COVID-19 pandemic brought the world to a standstill, and the development of vaccines became a global priority to combat the deadly virus. Among these vaccines, the mRNA-based ones, such as the mRNA-1273 vaccine, has been claimed to show efficacy in preventing severe disease and reducing transmission. However, concerns about potential adverse effects have been present since the vaccines' inception.
A new study conducted by the University of Basel sheds new light on one such adverse effect, vaccine-associated myocardial injury, revealing unexpected findings that challenge previous assumptions.
For a while now, it has been promoted by many so-called Western ‘experts’ along with various ‘manipulated studies; and
COVID-19 News reports in various mainstream news that SARS-CoV-2 infections are basically driving myocardial injury and heart issues and that these mRNA vaccines were not the main culprits behind a lot of sudden heart failure deaths. In reality, both SARS-CoV-2 infections and the mRNA jabs are causing myocardial injury and heart issues as the cardio-toxic spike proteins are the common denominator!
The study team set out to investigate the incidence rate and symptoms of myocardial injury, a condition characterized by inflammation of the heart muscle, following mRNA booster vaccinations.
The researchers, led by a team of dedicated scientists and clinicians, conducted a prospective active surveillance study involving 777 participants scheduled to receive the mRNA-1273 booster vaccination. The median age of the participants was 37 years, with 69.5% of them being women.
The study found that a surprising 5.1% of participants (around one in 35 people) had elevated high-sensitivity cardiac troponin T (hs-cTnT) concentration on day 3 after receiving the booster dose, indicating vaccine-associated myocardial injury.
The most astonishing revelation was that vaccine-associated myocardial injury was even more common than initially thought, occurring in approximately 2.8% of those who received the mRNA-1273 booster vaccine. These study team claimed that the injuries were generally mild and temporary, alleviating concerns over long-term consequences.
A deeper analysis of the data revealed a significant difference in vaccine-associated myocardial injury between women and men. The incidence rate of myocardial injury was 3.7% in women and only 0.8% in men. The researchers hypothesize that this discrepancy could be attributed to differences in vaccine dosage relative to body weight or myocardial mass between genders, suggesting dose-dependent toxic effects.
Various medical experts are now emphasizing the importance of this study's findings. They expressed concern that regulators worldwide must pay close attention to this information, as the incidence of vaccine-associated myocardial injury is higher than previously acknowledged, warranting serious consideration and further investigation.
Despite the concerning findings, the study team stressed that it is crucial to note that vaccine-associat
ed myocardial injury was mostly mild and transient, and no participant developed major adverse cardiac events within 30 days. The study's authors claimed that the overall risk-benefit ratio of booster vaccinations remains highly favorable for most individuals, given the significant protection the vaccines provide against COVID-19 and its severe complications.
The study also delved into possible immunological mechanisms underlying vaccine-associated myocardial injury.
Surprisingly, the study team found that the injury did not seem to be linked to antibodies neutralizing IL-1RA or pre-existing vaccine/infection-induced immunity against SARS-CoV-2. Instead, they observed lower levels of IFN-λ1(IL-29) and GM-CSF in cases with myocardial injury, suggesting potential roles of these factors in myocardial protection and warranting further investigation.
The study team acknowledged the need for further studies to assess the long-term impact of vaccine-associated myocardial injury on the risk of cardiac arrhythmias and heart failure. Moreover, the study's insights may help vaccine manufacturers optimize future vaccine doses and compositions to minimize adverse effects.
The study findings have brought essential information to light, challenging previous assumptions about vaccine-associated myocardial injury.
The study findings were published in the peer reviewed European Journal of Heart Failure.
https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2978
For the latest
COVID-19 News, keep on logging to Thailand Medical News.
Share
Tweet
Share
